Clinical Trial Update: A Study of RG1662 in Individuals With Down Syndrome [Phase 1]

View source ↗

Summary

A Phase 1 study of RG1662 in individuals with Down syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• RG1662

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Down Syndrome | Phase 1 | Status: COMPLETED